This fourth volume in the series offers unique insider insights into the drug development process, detailing the journey from initial drug candidate molecules to final marketed products. It begins with a general overview of drug discovery, followed by seven chapters featuring selected case studies on recently introduced drugs and drug classes, including small molecules and biopharmaceuticals across various therapeutic fields. The volume highlights trends in peptide-based drug discovery and the physicochemical properties of newly approved oral drugs. It also explores drug class studies, such as antibody-drug conjugates and the therapeutic potential of dopamine partial agonists. Notable case studies include the discovery of Etelcalcetide for secondary hyperparathyroidism in chronic kidney disease patients, the development of Lenvatinib Mesylate, and the discovery of Venetoclax. The book focuses on drugs not covered in textbooks, such as Ocrelizumab, an anti-CD-20 mAb for multiple sclerosis, and Venetoclax, a selective BCL-2 antagonist. Featuring personal experiences from successful drug developers in both industry and academia, this volume is endorsed by the International Union of Pure and Applied Chemistry (IUPAC) and serves as an informative reference for professionals in the pharmaceutical industry, chemists, and pharmacy educators.
